- Country profiles
- Data dashboard
- Satellite Pages
- About us
- WHAT'S NEW
This was the first year of the new funding cycle for the Multi-Country Western Pacific Integrated HIV/tuberculosis (TB) Programme. The three-year (2018-2020) US$11,368,713 programme is supported by the Global Fund and aims to strengthen control of HIV and TB in 11 Pacific island countries: Cook Islands, Federated States of Micronesia, Kiribati, Nauru, Niue, Palau, Republic of Marshall Islands, Samoa, Tonga, Tuvalu and Vanuatu. The United Nations Development Programme is the programme’s Principal Recipient.
Drug-resistant TB is part of the growing challenge of antimicrobial-resistant superbugs that do not respond to existing medications, resulting in fewer treatment options and increasing mortality rates for illnesses that would ordinarily be curable – including TB. Global development partners must move faster to contain this threat of antimicrobial resistance (AMR) before it escalates to claim millions of lives around the world.
TB remains one of the top 10 causes of death worldwide. Millions of people continue to fall sick from TB each year. The Global TB Report 2019 provides a comprehensive and up-to-date assessment of the TB epidemic, and progress in the response, at global, regional and country levels. It features data on disease trends and the response to the epidemic in 202 countries and territories.
The Global Report includes trends in TB incidence and mortality, data on case detection and treatment results for TB, multidrug-resistant TB (MDR-TB), TB/HIV, TB prevention, universal health coverage as well as financing. It presents progress towards targets set at the first-ever United Nations General Assembly high-level meeting on TB in 2018, that brought together heads of state, as well as the targets of the WHO End TB Strategy and the Sustainable Development Goals.
The report also includes an overview of pipelines for new TB diagnostics, drugs and vaccines. Additionally, it outlines a monitoring framework that features data on SDG indicators that can be used to identify key influences on the TB epidemic at national level and inform the multi-sectoral actions required to end the TB epidemic.
The aim of the people-centred framework is to help countries to develop fully prioritized and budgeted NSPs based on a culture of making full use of the available data, which are aligned with national planning cycles and which provide the basis for a robust national response that can accelerate progress towards the goal of ending TB. In addition, applying the framework for other possible applications according to the country’s planning and policy cycle encourages the culture of data utilization and evidence translation into decision making and planning.
The Annual Report of SAARC TB and HIV/AIDS Centre (STAC) is being presented indicating the programmes, activities and achievements of the year 2017. This is the Twenty-second consecutive comprehensive Annual Report STAC. This report includes a summary of the activities carried out by the Centre for the year 2017 along with introduction, goals, objectives, vision, mission and achievements of the Centre.
This Technical Brief provides practical guidance for countries in using a gender equity approach to maximize the impact of programs resourced by the Global Fund to Fight AIDS, Tuberculosis and Malaria (the Global Fund). Gender equity means everyone has an opportunity to attain their full health and well-being according to their respective needs, with no one disadvantaged due to gender norms, roles and relationships. The main audience for this brief is stakeholders who are directly involved in country-level processes to develop and write funding requests for the Global Fund.
This training manual was developed by TB-affected communites and TB activists to build and strengthen the capacity of people with and affected by TB to better understand the human rights issues and abuses they encounter and be able to respond constructively. Communities affected by TB include communities of people with TB disease, those who have previously had TB disease, and key populations like children, healthcare workers, indigenous peoples, people living with HIV, people who use drugs, prisoners, miners, mobile populations, women, the urban and rural poor, and their families, and dependents and their caregivers.
Providing evidence-based guidelines to inform public health service delivery for Member States and other stakeholders is one of the core responsibilities of the World Health Organization (WHO). To support countries in responding to the challenges of TB and drug-resistant TB, the WHO Global TB Programme regularly issues evidence-based guidelines using the international GRADE4 (Grading of Recommendations, Assessment, Development and Evaluation) approach for scientific evidence assessment.
The costing guidelines explain how to cost TB interventions from the perspective of the providers of health services. The provider perspective takes the point of view of the provision of services; the costs are those incurred by a hospital, clinic or TB facility providing the services. Tools for data collection referred to as the Value TB Costing Tool Suite are included.
Concerted and integrated efforts are needed to prevent and address both TB and TB-HIV burden in the region.
2 out of 3 TB infections globally are in Asia and the Pacific and 60% of MDR-TB burden is in this region. Globally, Asia and the Pacific is the home for 13% of PLHIV but 20% of TB-HIV co-infections are in this region. Systematic collaboration between TB-HIV programmes will save lives and improve the quality of life of people living with and affected by HIV and TB.